Hyloris Pharmaceuticals Sa · EURONEXT:HYL
Hyloris Pharmaceuticals Sa — Shareholder Meeting (June 2026)
48 slides from Hyloris Pharmaceuticals Sa's shareholder meeting presentation, Jun 9, 2026
Slide 1: Ordinary General Meeting
Ordinary General Meeting Welcome! Nice to meet you! 9 June 2026
Slide 2: Agenda
01 Opening of the Meeting 02 Convocation, Attendance & Voting principles 03 Strategic Update 2025, Financials, Remuneration 04 Questions 05 Resolutions Agenda items - Voting Agenda
Slide 3: Convocations, Attendance & Voting
Convocations, Attendance & Voting
Slide 4: Opening Meeting
Opening Meeting Ordinary General Meeting held on 9 June 2026 at 14:00 (Belgian time) in Liège, Belgium. The meeting bureau consist of Stefan Yee (Chairman) and Ann De Jaeger (General Secretary). French is the official language for minutes & resolutions; an English translation of the minutes will be
Slide 5: Convocation, Attendance & Voting principles
Convocation, Attendance & Voting principles The meeting was convened in accordance with the Belgian Code of Companies and Associations. Convening notices were published on 8 May 2026 and supporting documentation was made available on the Company website and ABN Amro Platform. Shareholders registered
Slide 6: Strategic Update by CEO 2025 - in Brief
Strategic Update by CEO 2025 - in Brief
Slide 7: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, “presentation” means this document, oral presenta
Slide 8: Pharma needs faster & more affordable innovation
Pharma needs faster & more affordable innovation The traditional way thousands only a of drug candidates are fraction in the pipeline make it to market worldwide Slow Expensive Risky
Slide 9: Our Mission
Our Mission We add value through Reinventing Existing Medications for unmet patient needs worldwide
Slide 10: Reinvent existing & Invent new medicines
Reinvent existing & Invent new medicines REFORMULATING REPURPOSING NCE Improve DOSAGE FORM and/or change Repurpose existing medicine for a ROUTE of administration of existing NEW therapeutic INDICATION (use) medicines New Chemical Entity Target to be MORE EFFECTIVE – MORE NEW PRODUCT – NEW FIELD usi
Slide 11: FDA's 505(b)(2) pathway as the engine
FDA’s 505(b)(2) pathway (or equivalent) as the engine Added value to healthcare system Addressing clear unmet needs Technical feasibility Clear scientific & medical rationale Fast market adoption Approved, well-known molecules ≤ 7 years to market Maximized ROI Defined regulatory pathway Large potent
Slide 12: Where others stop, we start and add value
Where others stop, we start and add value. Reinventing Existing Medicines for Unmet Patient Needs Worldwide 30+ 3 Innovation Engine 55 Products in pipeline Commercial products Team members Lowest Financial Loss Good Governance in Recurring Revenues since IPO / Place Improving No Financial Debt Hylor
Slide 13: Our Product Portfolio: 3 Strategic Focus Groups for Growth
Our Product Portfolio (as publicly announced) 3 Strategic Focus Groups for Growth MAVERICKS CORE DRIVERS PROMISING SEEDS A high-potential product backed A catalyst product building a An early-stage product pending with clinical evidence and strong recurring revenue base at clinical validation: signi
Slide 14: Our Product Portfolio: 3 Strategic Focus Groups for Growth
Our Product Portfolio (as publicly announced) Product Fiches will be shared separately 3 Strategic Focus Groups for Growth MAVERICKS CORE DRIVERS PROMISING SEEDS HY-094 (Iron Deficiency Anemia) Maxigesic® IV HY-083 (Idiopathic Rhinitis) Milrinone ER Sotalol IV HY-095 (Equine Gastric Ulcers) Miconazo
Slide 15: New Products Added in 2025
6 New Products Added in 2025 Hitting our ambitious 30+ portfolio target
Slide 16: New Product Candidates Added in 2025
6 New Product Candidates Added in 2025 From reformulations to NCEs and NBEs — a landmark year for pipeline expansion Pantoprazole IV RTU Ondansetron ER HY-094 Iron IV Reformulation Reformulation New Chemical Entity (NCE) • Ready-to-use IV formulation — no • Novel 3rd-gen IV iron deficiency therapy (
Slide 17: Clinical Trial Results in 2025
4 Clinical Trial Results in 2025 Delivering data that moves the needle for patients
Slide 18: Clinical Trial Results in 2025
4 Clinical Trial Results in 2025 Four key readouts — reinforcing our pipeline and supporting regulatory progression Atomoxetine Oral Liquid Aspirin IV ✓ POSITIVE DATA · ADHD — oral liquid formulation ✓ POSITIVE PIVOTAL DATA · Acute care — intravenous aspirin • Clinical data package completed and pro
Slide 19: Out-Licensing Deals in 2025
8 Out-Licensing Deals in 2025 Expanding global reach through strategic partnerships
Slide 20: Out-Licensing Deals in 2025
8 Out-Licensing Deals in 2025 Hyloris executed 8 agreements in 2025, covering 5 products across major geographies worldwide XTRAZA® (TXA Oromucosal) Colonis United Kingdom Exclusive license & supply Huons South Korea Exclusive license & supply AFT Pharmaceuticals AUS, NZ, CA, ZA Exclusive license &
Slide 21: Early 2026: Continuing the Momentum
Early 2026: Continuing the Momentum Key developments already achieved in the first months of 2026 Orion Partnership — Pantoprazole IV RTU (19 Jan 2026) Atomoxetine Oral Liquid — NDA Filed with U.S. FDA • NDA submitted to U.S. FDA following completion of clinical data • Exclusive license & supply agr
Slide 22: 2026 Milestones Ahead
2026 Milestones Ahead Key clinical, regulatory and commercial milestones expected in 2026 CLINICAL REGULATORY COMMERCIAL • Phase 3 starts: HY-094 (Iron IV), Suramin IV • Submissions: Dofetilide IV, Phosphate • TXA RTU: launch with Orion across Europe • Phase 1 starts: ARBM-101 Oral Liquid • Pantopra
Slide 23: HY-094 Ferric for injection
HY-094 Ferric for injection Indication: Iron Deficiency Anemia (IDA) Global Intravenous Iron Drugs Market Size 2023 to 2034 (USD Billion) 9 • Innovative NCE injectable iron therapy designed to overcome limitations of 8 current treatments for better convenience and tolerability 7 • Targeting global i
Slide 24: Alenura
Alenura Indication: Interstitial Cystitis/Bladder Pain Syndrome • Defect in inner lining of the bladder = chronic, recurring discomfort & pain Proven pain reduction in 2 • Alenura 15mL prefilled syringe with a dual mode of action: controlled Ph2 trials • Alkalinised lidocaine: penetrates bladder wal
Slide 25: HY-083 Idiopathic Rhinitis
HY-083 Indication: Idiopathic Rhinitis - chronic rhinitis without a known cause • Symptoms: Runny nose, stuffy nose, sneezing fits without a medical diagnosis (allergies, infection, inflammation, …) • Impacting quality of life daily (sleep patterns, drowsiness, irritability, poor concentration) • Mo
Slide 26: Our Strategy
Our Strategy Multiple shots on goal Lower risk as we start 30+ Potential from Innovative, existing value-added Multiple drug drugs game changer, near term filings candidates ** geared for growth ≤ €7 million average cost to market* 3 products commmercialised Ambition to become the ≤ 7 years to marke
Slide 27: Annual Reports – FY 2025 accounts
Annual Reports – FY 2025 accounts
Slide 28: Financial Highlights 2025
Financial Highlights 2025 (in € thousand) 2025 2024 % change Statement of financial position Intangible assets increased mainly following the Methanobactin (ArborMed) Non current assets 13,398 11,628 +15% acquisition. Intangible assets 5,689 3,838 +48% Right-of-use assets relate primarily to vehicle
Slide 29: Financial Highlights 2025
Financial Highlights 2025 (in € thousand) 2025 2024 % change Statement of financial position Solid Equity position of €26.5 million thanks to a contained net loss of €6,3 Equity 26,475 32,143 (18%) million. Share capital 140 140 0% Borrowings mainly comprise IFRS 16 lease liabilities related to vehi
Slide 30: Financial Highlights 2025
Financial Highlights 2025 Operating Income Operating income amounted to €8,832 thousand in 2025, compared to €10,043 thousand in 2024, primarily reflecting a lower contribution from (in € thousand) 2025 2024 % change non-recurring milestone income, partly offset by robust growth in royalty revenues.
Slide 31: Remuneration policy & report (CLO)
Remuneration policy & report (CLO)
Slide 32: Executive Committee Remuneration (2025)
Executive Committee Remuneration (2025) Component (€) Co-CEOs Other ExCom Members Annual base salary 384,257 682,150 Short-term variable 69,022 47,462 remuneration Board Remuneration (2025) Supplementary n.a. n.a. pension Name Remuneration (€) Car/transport n.a. n.a. Stefan Yee 27,500 allowance Leon
Slide 33: Updated Remuneration Policy – Key Amendments
Updated Remuneration Policy – Key Amendments Submitted for AGM approval (binding shareholder vote). Changes agreed in principle by the RNC on 18 March 2026. 1) LTI Framework: Formal inclusion of LTI - warrant/ESOP mechanism within executive remuneration (and for key employees). 2) Chairman Fee: Refl
Slide 34: Q&A
Q&A
Slide 35: Agenda Items — Resolutions
aw Agenda Items — Resolutions
Slide 36: Resolutions – Agenda Items
Resolutions – Agenda Items 1. Take cognizance of the Board of Directors’ annual report for the financial year ending on the 31st of December 2025. 2. Take cognizance of the statutory auditor’s audit report for the financial year ending on the 31st of December 2025. 3. Approve the non-consolidated an
Slide 37: Questions
Questions Shareholders were invited to ask questions on agenda items: no questions received prior to the meeting. No additional agenda requests were submitted before the meeting. Minutes will be published online after meeting.
Slide 38: Agenda Item 1
Agenda Item 1 Take cognizance of the Board of Directors’ annual report for the financial year ending on the 31st of December 2025. Prendre connaissance du rapport annuel du Conseil d’Administration relatif à l’exercice clos le 31 décembre 2025. Proposed Resolution: This agenda item does not require
Slide 39: Agenda Item 2
Agenda Item 2 Take cognizance of the statutory auditor’s audit report for the financial year ending on the 31st of December 2025. Prendre connaissance du rapport annuel du commissaire relatif à l’exercice clos le 31 décembre 2025. Proposed Resolution: This agenda item does not require a resolution.
Slide 40: Agenda Item 3
Agenda Item 3 Approve the non-consolidated annual accounts for the financial year ending on the 31st of December 2025 and approve the profit-and-loss allocation set out therein. Approuver les comptes annuels statutaires de l’exercice clos le 31 décembre 2025 et l’affectation du résultat qui y est re
Slide 41: Agenda Item 4
Agenda Item 4 Take cognizance of the Board of Directors’ and the statutory auditor's reports on the consolidated annual accounts for the financial year ending on the 31st of December 2025. Prendre connaissance des rapports du Conseil d’Administration et du commissaire portant sur les comptes annuels
Slide 42: Agenda Item 5
Agenda Item 5 Take cognizance of the consolidated annual accounts for the financial year ending on the 31st of December 2025. Prendre connaissance des comptes annuels consolidés de l’exercice clos le 31 décembre 2025. Proposed Resolution: This agenda item does not require a resolution. The Meeting t
Slide 43: Agenda Item 6
Agenda Item 6 Grant discharge to the directors. Donner décharge aux administrateurs. Proposed Resolution: Proposed to grant discharge to each director for the performance of duties during FY2025. Voting Result FOR AGAINST ABSTAIN [●] [●] [●]
Slide 44: Agenda Item 7
Agenda Item 7 Grant discharge to the statutory auditor. Donner décharge au commissaire. Proposed Resolution: Proposed to grant discharge to the statutory auditor, BDO Réviseurs d'Entreprises SRL, represented by Mr. Christophe Pelzer, for FY2025. Voting Result FOR AGAINST ABSTAIN [●] [●] [●]
Slide 45: Agenda Item 8
Agenda Item 8 Vote (advisory vote) on the remuneration report for the financial year ending on the 31st of December 2025. Voter (vote consultatif) sur le rapport de rémunération pour l'exercice clos le 31 décembre 2025. Proposed Resolution: Proposed to approve the remuneration report for FY2025 as i
Slide 46: Agenda Item 9
Agenda Item 9 Approve the amended remuneration policy 2026-2029. Approuver la politique de rémunération 2026 - 2029 modifiée. Proposed Resolution: Proposed to approve the amended remuneration policy 2026–2029. Voting Result FOR AGAINST ABSTAIN [●] [●] [●]
Slide 47: Agenda Item 10
Agenda Item 10 Grant power of attorney for the performance of formalities. Donner procuration pour l'accomplissement des formalités. Proposed Resolution: This agenda item does not require a resolution. The Meeting takes note of the Board of Directors’ report for FY2025.
Slide 48: Value Starts Here
Value Starts Here Hyloris Pharmaceuticals SA - 2026 HQ: Boulevard Patience Et Beaujonc N°3/1 4000 Liège, Belgium +32(0)4 346 02 07 contact@hyloris.com investorrelations@hyloris.com
Hyloris Pharmaceuticals — Shareholder Meeting (June 2026) on 6ix